Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Stock Competitors & Peer Comparison
See APLS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for APLS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| APLS | $41.03 | +0.00% | 5.3B | 38.35 | $1.07 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
APLS vs VRTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas VRTX's P/E ratio is 25.35. In terms of profitability, APLS's ROE is +0.40%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, APLS is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
APLS vs REGN Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas REGN's P/E ratio is 16.71. In terms of profitability, APLS's ROE is +0.40%, compared to REGN's ROE of +0.18%. Regarding short-term risk, APLS is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for APLS.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
APLS vs VRNA Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas VRNA's P/E ratio is -102.80. In terms of profitability, APLS's ROE is +0.40%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, APLS is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for APLS.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
APLS vs ARGX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ARGX's P/E ratio is 78.75. In terms of profitability, APLS's ROE is +0.40%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, APLS is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
APLS vs SGEN Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas SGEN's P/E ratio is -57.19. In terms of profitability, APLS's ROE is +0.40%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, APLS is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for APLS.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
APLS vs RVMDW Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, APLS's ROE is +0.40%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, APLS is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for APLS.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
APLS vs RVMD Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas RVMD's P/E ratio is -26.52. In terms of profitability, APLS's ROE is +0.40%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, APLS is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for APLS.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
APLS vs ONC Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ONC's P/E ratio is 70.70. In terms of profitability, APLS's ROE is +0.40%, compared to ONC's ROE of +0.12%. Regarding short-term risk, APLS is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
APLS vs ALNY Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ALNY's P/E ratio is 37.02. In terms of profitability, APLS's ROE is +0.40%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, APLS is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
APLS vs ROIV Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ROIV's P/E ratio is -34.86. In terms of profitability, APLS's ROE is +0.40%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, APLS is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
APLS vs INCY Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas INCY's P/E ratio is 16.06. In terms of profitability, APLS's ROE is +0.40%, compared to INCY's ROE of +0.30%. Regarding short-term risk, APLS is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for APLS.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
APLS vs BNTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas BNTX's P/E ratio is -19.61. In terms of profitability, APLS's ROE is +0.40%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, APLS is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
APLS vs UTHR Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas UTHR's P/E ratio is 19.10. In terms of profitability, APLS's ROE is +0.40%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, APLS is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for APLS.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
APLS vs MRNA Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas MRNA's P/E ratio is -6.73. In terms of profitability, APLS's ROE is +0.40%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, APLS is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for APLS.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
APLS vs INSM Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas INSM's P/E ratio is -17.15. In terms of profitability, APLS's ROE is +0.40%, compared to INSM's ROE of -1.30%. Regarding short-term risk, APLS is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for APLS.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
APLS vs BGNE Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas BGNE's P/E ratio is -22.55. In terms of profitability, APLS's ROE is +0.40%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, APLS is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for APLS.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
APLS vs DNA-WT Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, APLS's ROE is +0.40%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, APLS is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for APLS.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
APLS vs GMAB Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas GMAB's P/E ratio is 20.77. In terms of profitability, APLS's ROE is +0.40%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, APLS is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for APLS.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
APLS vs NBIX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas NBIX's P/E ratio is 24.10. In terms of profitability, APLS's ROE is +0.40%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, APLS is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
APLS vs JAZZ Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, APLS's ROE is +0.40%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, APLS is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for APLS.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
APLS vs BBIO Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas BBIO's P/E ratio is -21.41. In terms of profitability, APLS's ROE is +0.40%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, APLS is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for APLS.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
APLS vs ASND Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ASND's P/E ratio is -100.79. In terms of profitability, APLS's ROE is +0.40%, compared to ASND's ROE of -56.42%. Regarding short-term risk, APLS is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
APLS vs EXEL Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas EXEL's P/E ratio is 15.88. In terms of profitability, APLS's ROE is +0.40%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, APLS is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for APLS.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
APLS vs KRTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas KRTX's P/E ratio is -28.09. In terms of profitability, APLS's ROE is +0.40%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, APLS is less volatile compared to KRTX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
APLS vs ARWR Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ARWR's P/E ratio is -39.37. In terms of profitability, APLS's ROE is +0.40%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, APLS is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
APLS vs BMRN Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas BMRN's P/E ratio is 28.86. In terms of profitability, APLS's ROE is +0.40%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, APLS is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for APLS.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
APLS vs TECH Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas TECH's P/E ratio is 37.16. In terms of profitability, APLS's ROE is +0.40%, compared to TECH's ROE of +0.05%. Regarding short-term risk, APLS is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for APLS.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
APLS vs RNAM Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas RNAM's P/E ratio is -17.39. In terms of profitability, APLS's ROE is +0.40%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, APLS is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for APLS.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
APLS vs AXSM Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas AXSM's P/E ratio is -56.92. In terms of profitability, APLS's ROE is +0.40%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, APLS is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for APLS.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
APLS vs MDGL Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas MDGL's P/E ratio is -36.51. In terms of profitability, APLS's ROE is +0.40%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, APLS is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for APLS.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
APLS vs SMMT Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas SMMT's P/E ratio is -8.14. In terms of profitability, APLS's ROE is +0.40%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, APLS is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for APLS.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
APLS vs KRYS Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas KRYS's P/E ratio is 45.60. In terms of profitability, APLS's ROE is +0.40%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, APLS is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for APLS.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
APLS vs HALO Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas HALO's P/E ratio is 17.87. In terms of profitability, APLS's ROE is +0.40%, compared to HALO's ROE of +1.26%. Regarding short-term risk, APLS is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for APLS.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
APLS vs CYTK Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CYTK's P/E ratio is -13.23. In terms of profitability, APLS's ROE is +0.40%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, APLS is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for APLS.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
APLS vs RXDX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas RXDX's P/E ratio is -56.47. In terms of profitability, APLS's ROE is +0.40%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, APLS is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for APLS.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
APLS vs ABVX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ABVX's P/E ratio is -65.48. In terms of profitability, APLS's ROE is +0.40%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, APLS is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
APLS vs NUVL Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas NUVL's P/E ratio is -21.79. In terms of profitability, APLS's ROE is +0.40%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, APLS is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for APLS.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
APLS vs CRNX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CRNX's P/E ratio is -16.28. In terms of profitability, APLS's ROE is +0.40%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, APLS is less volatile compared to CRNX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
APLS vs PTGX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas PTGX's P/E ratio is -75.49. In terms of profitability, APLS's ROE is +0.40%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, APLS is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
APLS vs IMGN Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas IMGN's P/E ratio is -111.55. In terms of profitability, APLS's ROE is +0.40%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, APLS is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for APLS.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
APLS vs IONS Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas IONS's P/E ratio is -30.10. In terms of profitability, APLS's ROE is +0.40%, compared to IONS's ROE of -1.11%. Regarding short-term risk, APLS is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for APLS.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
APLS vs PRAX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas PRAX's P/E ratio is -23.02. In terms of profitability, APLS's ROE is +0.40%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, APLS is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
APLS vs SYRE Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas SYRE's P/E ratio is -47.27. In terms of profitability, APLS's ROE is +0.40%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, APLS is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for APLS.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
APLS vs KYMR Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas KYMR's P/E ratio is -29.29. In terms of profitability, APLS's ROE is +0.40%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, APLS is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for APLS.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
APLS vs ALKS Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ALKS's P/E ratio is 52.66. In terms of profitability, APLS's ROE is +0.40%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, APLS is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
APLS vs BPMC Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas BPMC's P/E ratio is -51.58. In terms of profitability, APLS's ROE is +0.40%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, APLS is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for APLS.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
APLS vs APGE Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas APGE's P/E ratio is -30.97. In terms of profitability, APLS's ROE is +0.40%, compared to APGE's ROE of -0.33%. Regarding short-term risk, APLS is less volatile compared to APGE. This indicates lower risk in terms of short-term price fluctuations for APLS.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
APLS vs CERE Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CERE's P/E ratio is -16.47. In terms of profitability, APLS's ROE is +0.40%, compared to CERE's ROE of -0.72%. Regarding short-term risk, APLS is less volatile compared to CERE. This indicates lower risk in terms of short-term price fluctuations for APLS.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
APLS vs TGTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas TGTX's P/E ratio is 17.88. In terms of profitability, APLS's ROE is +0.40%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, APLS is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
APLS vs IMVT Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas IMVT's P/E ratio is -14.46. In terms of profitability, APLS's ROE is +0.40%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, APLS is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for APLS.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
APLS vs PCVX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas PCVX's P/E ratio is -7.86. In terms of profitability, APLS's ROE is +0.40%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, APLS is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
APLS vs IBRX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas IBRX's P/E ratio is -8.44. In terms of profitability, APLS's ROE is +0.40%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, APLS is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
APLS vs MTSR Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas MTSR's P/E ratio is -23.58. In terms of profitability, APLS's ROE is +0.40%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, APLS is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for APLS.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
APLS vs MRUS Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas MRUS's P/E ratio is -17.05. In terms of profitability, APLS's ROE is +0.40%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, APLS is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for APLS.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
APLS vs RYTM Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas RYTM's P/E ratio is -31.71. In terms of profitability, APLS's ROE is +0.40%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, APLS is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for APLS.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
APLS vs ACLX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ACLX's P/E ratio is -28.27. In terms of profitability, APLS's ROE is +0.40%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, APLS is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for APLS.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
APLS vs COGT Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas COGT's P/E ratio is -18.45. In terms of profitability, APLS's ROE is +0.40%, compared to COGT's ROE of -0.83%. Regarding short-term risk, APLS is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for APLS.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
APLS vs RETA Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas RETA's P/E ratio is -66.29. In terms of profitability, APLS's ROE is +0.40%, compared to RETA's ROE of +0.47%. Regarding short-term risk, APLS is less volatile compared to RETA. This indicates lower risk in terms of short-term price fluctuations for APLS.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
APLS vs MIRM Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas MIRM's P/E ratio is -7.78. In terms of profitability, APLS's ROE is +0.40%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, APLS is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for APLS.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
APLS vs BLTE Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas BLTE's P/E ratio is -84.82. In terms of profitability, APLS's ROE is +0.40%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, APLS is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for APLS.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
APLS vs ERAS Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ERAS's P/E ratio is -19.51. In terms of profitability, APLS's ROE is +0.40%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, APLS is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
APLS vs CGON Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CGON's P/E ratio is -30.55. In terms of profitability, APLS's ROE is +0.40%, compared to CGON's ROE of -0.23%. Regarding short-term risk, APLS is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for APLS.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
APLS vs CNTA Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CNTA's P/E ratio is -22.63. In terms of profitability, APLS's ROE is +0.40%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, APLS is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for APLS.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
APLS vs XENE Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas XENE's P/E ratio is -13.33. In terms of profitability, APLS's ROE is +0.40%, compared to XENE's ROE of -0.49%. Regarding short-term risk, APLS is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for APLS.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
APLS vs LGND Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas LGND's P/E ratio is 34.48. In terms of profitability, APLS's ROE is +0.40%, compared to LGND's ROE of +0.16%. Regarding short-term risk, APLS is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for APLS.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
APLS vs SRRK Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas SRRK's P/E ratio is -13.17. In terms of profitability, APLS's ROE is +0.40%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, APLS is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for APLS.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
APLS vs PTCT Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas PTCT's P/E ratio is -29.19. In terms of profitability, APLS's ROE is +0.40%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, APLS is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for APLS.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
APLS vs CDTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CDTX's P/E ratio is -19.77. In terms of profitability, APLS's ROE is +0.40%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, APLS is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for APLS.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
APLS vs ABCM Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, APLS's ROE is +0.40%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, APLS is less volatile compared to ABCM. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
APLS vs ISEE Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ISEE's P/E ratio is -22.44. In terms of profitability, APLS's ROE is +0.40%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, APLS is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
APLS vs TVTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas TVTX's P/E ratio is -254.05. In terms of profitability, APLS's ROE is +0.40%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, APLS is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
APLS vs TERN Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas TERN's P/E ratio is -51.41. In terms of profitability, APLS's ROE is +0.40%, compared to TERN's ROE of -0.20%. Regarding short-term risk, APLS is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for APLS.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
APLS vs DFTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas DFTX's P/E ratio is N/A. In terms of profitability, APLS's ROE is +0.40%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, APLS is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
APLS vs DYN Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas DYN's P/E ratio is -7.82. In terms of profitability, APLS's ROE is +0.40%, compared to DYN's ROE of -0.64%. Regarding short-term risk, APLS is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for APLS.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
APLS vs CRSP Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CRSP's P/E ratio is -9.39. In terms of profitability, APLS's ROE is +0.40%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, APLS is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for APLS.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
APLS vs FOLD Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas FOLD's P/E ratio is -161.00. In terms of profitability, APLS's ROE is +0.40%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, APLS is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for APLS.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
APLS vs AKRO Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas AKRO's P/E ratio is -14.57. In terms of profitability, APLS's ROE is +0.40%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, APLS is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for APLS.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
APLS vs DNTH Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas DNTH's P/E ratio is -25.89. In terms of profitability, APLS's ROE is +0.40%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, APLS is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for APLS.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
APLS vs ALPN Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ALPN's P/E ratio is -101.52. In terms of profitability, APLS's ROE is +0.40%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, APLS is similarly volatile compared to ALPN. This indicates similar risk in terms of short-term price fluctuations for APLS.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
APLS vs ACAD Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ACAD's P/E ratio is 12.68. In terms of profitability, APLS's ROE is +0.40%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, APLS is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
APLS vs CAI Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CAI's P/E ratio is -86.19. In terms of profitability, APLS's ROE is +0.40%, compared to CAI's ROE of +0.06%. Regarding short-term risk, APLS is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for APLS.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
APLS vs MANE Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas MANE's P/E ratio is -33.36. In terms of profitability, APLS's ROE is +0.40%, compared to MANE's ROE of -0.84%. Regarding short-term risk, APLS is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for APLS.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
APLS vs OPT Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas OPT's P/E ratio is -1.52. In terms of profitability, APLS's ROE is +0.40%, compared to OPT's ROE of +1.18%. Regarding short-term risk, APLS is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for APLS.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
APLS vs PRTC Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas PRTC's P/E ratio is -3.78. In terms of profitability, APLS's ROE is +0.40%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, APLS is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for APLS.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
APLS vs CELC Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CELC's P/E ratio is -22.15. In terms of profitability, APLS's ROE is +0.40%, compared to CELC's ROE of -2.45%. Regarding short-term risk, APLS is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for APLS.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
APLS vs EWTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas EWTX's P/E ratio is -23.15. In terms of profitability, APLS's ROE is +0.40%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, APLS is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
APLS vs MRTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas MRTX's P/E ratio is -4.82. In terms of profitability, APLS's ROE is +0.40%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, APLS is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
APLS vs ELVN Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ELVN's P/E ratio is -32.82. In terms of profitability, APLS's ROE is +0.40%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, APLS is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
APLS vs CPRX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CPRX's P/E ratio is 12.30. In terms of profitability, APLS's ROE is +0.40%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, APLS is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for APLS.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
APLS vs RYZB Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas RYZB's P/E ratio is -57.86. In terms of profitability, APLS's ROE is +0.40%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, APLS is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for APLS.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
APLS vs CBAY Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas CBAY's P/E ratio is -32.81. In terms of profitability, APLS's ROE is +0.40%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, APLS is less volatile compared to CBAY. This indicates lower risk in terms of short-term price fluctuations for APLS.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
APLS vs VKTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas VKTX's P/E ratio is -7.67. In terms of profitability, APLS's ROE is +0.40%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, APLS is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for APLS.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
APLS vs DNLI Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas DNLI's P/E ratio is -7.99. In terms of profitability, APLS's ROE is +0.40%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, APLS is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for APLS.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
APLS vs ORKA Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ORKA's P/E ratio is -49.75. In terms of profitability, APLS's ROE is +0.40%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, APLS is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
APLS vs ADPT Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ADPT's P/E ratio is -41.80. In terms of profitability, APLS's ROE is +0.40%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, APLS is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
APLS vs ALMS Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ALMS's P/E ratio is -7.39. In terms of profitability, APLS's ROE is +0.40%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, APLS is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
APLS vs RCUS Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas RCUS's P/E ratio is -8.66. In terms of profitability, APLS's ROE is +0.40%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, APLS is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for APLS.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
APLS vs SWTX Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas SWTX's P/E ratio is -13.78. In terms of profitability, APLS's ROE is +0.40%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, APLS is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for APLS.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
APLS vs ARQT Comparison August 2026
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.3B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, APLS is priced at $41.03 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 38.35, whereas ARQT's P/E ratio is -933.00. In terms of profitability, APLS's ROE is +0.40%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, APLS is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for APLS.Check ARQT's competition here